

## THE ESSENTIAL GUIDE

### Association

The US Hereditary Angioedema Association. <https://www.haea.org/>

### Key Studies and Papers (*alphabetical by author*)

Agostoni A, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. *J Allergy Clin Immunol.* 2004;114:S51-S131.  
<https://www.ncbi.nlm.nih.gov/pubmed/15356535>

Bork K, et al. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. *J Allergy Clin Immunol.* 2012;130:692-697.  
<https://www.ncbi.nlm.nih.gov/pubmed/22841766?dopt=Abstract>

Bork K, et al. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. *Am J Med.* 2006;119:267-274. <https://www.ncbi.nlm.nih.gov/pubmed/16490473>

Bowen T, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. *Allergy Asthma Clin Immunol.* 2010;6:24.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921362/>

Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. *Br J Dermatol.* 2009;161:1153-1158. <https://www.ncbi.nlm.nih.gov/pubmed/19709101>

Bygum A, et al. The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology. *BMC Dermatol.* 2012;12:4.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439346/>

Bygum A, et al. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. *Eur J Dermatol.* 2009;19:147-151.  
<https://www.ncbi.nlm.nih.gov/pubmed/19264579>

Cicardi M, et al.; HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. *Allergy* 2012;67:147-157.  
<http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2011.02751.x/pdf>

Cichon S, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. *Am J Hum Genet.* 2006;79:1098-1104.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1698720/>

Craig T, et al. WAO Guideline for the Management of Hereditary Angioedema. *World Allergy Organis J.* 2012;5:182-199. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651186/>

Dagen C, et al. Treatment of Hereditary Angioedema: items that need to be addressed in practice parameter. *Allergy Asthma Clin Immunol.* 2010;6:11.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2887436/>

Frank MM. Hereditary angioedema: the clinical syndrome and its management in the United States. *Immunol Allergy Clin N Am.* 2006;26:653-668. <https://www.ncbi.nlm.nih.gov/pubmed/17085283>

Frank MM, et al. Hereditary angioedema: the clinical syndrome and its management. *Ann Int Med.* 1976;84:580-593. <https://www.ncbi.nlm.nih.gov/pubmed/1275365>

Lang DM, et al. International consensus on hereditary and acquired angioedema. *Ann Allergy Asthma Immunol.* 2012;109:395-402. <https://www.ncbi.nlm.nih.gov/pubmed/23176876>

Levi M, et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. *J Allergy Clin Immunol.* 2006;117:904-908. <https://www.ncbi.nlm.nih.gov/pubmed/16630950>

Longhurst HJ, et al. HAE international home therapy consensus document. *Allergy Asthma Clin Immunol.* 2010;6:22. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2922091/>

Riedl MA. Creating a comprehensive treatment plan for hereditary angioedema. *Immunol Allergy Clin N Am.* 2013;33:471-485. <https://www.ncbi.nlm.nih.gov/pubmed/24176212>

Roche O, et al. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. *Ann Allergy Asthma Immunol.* 2005;94:498-503.

<https://www.ncbi.nlm.nih.gov/pubmed/15875532>

Zuraw BL, et al.; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. *J Allergy Clin Immunol.* 2013;131:1491-1493. <https://www.ncbi.nlm.nih.gov/pubmed/23726531>

Zuraw BL, et al. Detection of C1 inhibitor mutations in patients with hereditary angioedema. *J Allergy Clin Immunol.* 2000;105:541-546. <https://www.ncbi.nlm.nih.gov/labs/articles/10719305/>

Zuraw BL. Novel therapies for hereditary angioedema. *Immunol Allergy Clin North Am.* 2006;26:691-708. <https://www.ncbi.nlm.nih.gov/pubmed/17085285>

Zuraw BL, et al.; US Hereditary Angioedema Association Medical Advisory Board. US Hereditary Angioedema Association Medical Advisory Board 2013 Recommendations for the Management of Hereditary Angioedema Due to C1 Inhibitor Deficiency. *J Allergy Clin Immunol Pract.* 2013;1:458-467. [http://www.haea.org/wp-content/uploads/recommendations\\_2013.pdf](http://www.haea.org/wp-content/uploads/recommendations_2013.pdf)